NinePointTwo Capital’s Pfizer PFE Stock Holding History

NinePointTwo Capital’s Portfolio PFE Stock Details PFE Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2023 Q4	–	Sell	-6,230	Closed	-$206K	–	281
2023 Q3	$206K	Hold	6,230	–	–	0.08%	203
2023 Q2	$228K	Hold	6,230	–	–	0.09%	171
2023 Q1	$254K	Buy	+6,230	New	+$269K	0.1%	125

Other funds holding PFE

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

Wellington Management Group Boston, Massachusetts $535B AUM 26.23% 1-Year Est. Return

Capital World Investors Los Angeles, California $733B AUM 35.63% 1-Year Est. Return

Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return

Charles Schwab San Francisco, California $654B AUM 26.35% 1-Year Est. Return

Norges Bank Oslo, Norway $935B AUM

Massachusetts Financial Services Boston, Massachusetts $298B AUM 21.96% 1-Year Est. Return

NinePointTwo Capital's PFE Position: Q4 2023 in Review

NinePointTwo Capital sold out of Pfizer (PFE) in Q4 2023, closing a stake of 6,230 shares — an estimated $206K sold.

NinePointTwo Capital first reported a position in PFE in Q1 2023 and held it in 3 quarters. The position peaked at $254K in Q1 2023. 2,935 funds tracked by Wall St. Rank hold PFE as of Q4 2023.

NinePointTwo Capital reported no remaining Pfizer position as of Q4 2023 after selling out during the quarter.
NinePointTwo Capital sold 6,230 Pfizer shares in Q4 2023, an estimated $206K.
NinePointTwo Capital first reported a position in Pfizer in Q1 2023 and held it in 3 quarters.
NinePointTwo Capital's Pfizer position peaked at $254K in Q1 2023.
2,935 funds tracked by Wall St. Rank held Pfizer as of Q4 2023.

Based on NinePointTwo Capital's 13F filing for Q4 2023, filed 14 Feb 2024.